But a challenge to an Orange Book patent, should a brand-name manufacturer decide to fight in court, also delays a generic’s approval for 30 months. The FTC says that drugmakers needlessly list ...
What Happened: The FTC is disputing “junk patent listings” for diabetes, weight loss, asthma and COPD drugs. This initiative represents the latest endeavor against what the agency perceives as ...
After the FTC’s November action, several manufacturers de-listed patents and three top drugmakers announced they would cap inhaler out-of-pocket costs at $35. “By filing bogus patent listings, pharma ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk ... on," FTC Chair Lina Khan said. The agency sent letters to 10 companies, warning that their patent listings were ...
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining ... they rely on,” FTC Chair Lina Khan ...
And they don't really have the inside view of what's happening at the FDA.” Gabriel: If drug manufacturers don’t remove their junk patent listings, they’ll open themselves up to antitrust lawsuits, ...
FTC’s latest action targets more than 300 Orange Book patent listings across 10 different companies, which brings the total to more than 400 patent listings across 14 companies and should send a ...
Most recently, on April 30, 2024, the FTC initiated a second round of patent listing disputes – this one targeting more than 300 device patent listings for 20 medicines approved to treat ...